Get the Stockscreener App
36.10
0.61%
0.22
Assembly Biosciences Inc stock is traded at $36.10, with a volume of 179.20K.
It is up +0.61% in the last 24 hours and up +0.70% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$35.88
Open:
$35.82
24h Volume:
179.20K
Relative Volume:
1.30
Market Cap:
$571.00M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-2.6702
EPS:
-13.5194
Net Cash Flow:
$22.49M
1W Performance:
+3.11%
1M Performance:
+0.70%
6M Performance:
+111.11%
1Y Performance:
+135.18%
1-Day Range:
$35.25
$36.92
1-Week Range:
$34.42
$38.82
52-Week Range:
$7.75
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
36.10 | 567.52M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
(ASMB) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
JANUS HENDERSON GROUP PLC Expands Stake in Assembly Biosciences Inc - GuruFocus
Assembly Biosciences (ASMB) Receives a Buy from Guggenheim - The Globe and Mail
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data By Investing.com - Investing.com South Africa
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data - Investing.com Nigeria
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance - Nasdaq
Assembly Biosciences stock rises after promising HSV drug results By Investing.com - Investing.com India
Assembly Biosciences Reports Positive Phase 1b Results - TipRanks
Assembly Biosciences stock rises after promising HSV drug results - Investing.com
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials - TipRanks
Assembly Bio reports strong results for HSV treatments in trials By Investing.com - Investing.com India
Assembly Biosciences (ASMB) Reports Promising Phase 1b Interim R - GuruFocus
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rat - The Manila Times
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will Assembly Biosciences Inc. (V7B) stock beat growth indexesWeekly Gains Report & Precise Swing Trade Alerts - Newser
Why ETFs are accumulating Assembly Biosciences Inc. (V7B) stockGap Up & High Yield Stock Recommendations - Newser
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) Shift From Loss To Profit - Yahoo Finance
Why Assembly Biosciences Inc. (V7B) stock is a strong analyst pick - Newser
Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 8.3%Time to Sell? - MarketBeat
Responsive Playbooks and the ASMB Inflection - news.stocktradersdaily.com
Can Assembly Biosciences Inc. (V7B) stock test all time highsJuly 2025 Momentum & Safe Capital Growth Trade Ideas - Newser
Will Assembly Biosciences Inc. (V7B) stock see insider accumulationEarnings Recap Summary & AI Enhanced Trading Alerts - Newser
Financial Comparison: Assembly Biosciences (NASDAQ:ASMB) versus Evoke Pharma (NASDAQ:EVOK) - Defense World
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Analyzing Evoke Pharma (NASDAQ:EVOK) & Assembly Biosciences (NASDAQ:ASMB) - Defense World
H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data - MSN
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Assembly Biosciences (ASMB) - The Globe and Mail
Understanding the Setup: (ASMB) and Scalable Risk - news.stocktradersdaily.com
Will Assembly Biosciences Inc. stock outperform international peersWeekly Market Outlook & Smart Investment Allocation Tips - newser.com
What analysts say about Assembly Biosciences Inc stockCurrency Fluctuation Impact & Double Or Triple Investment - earlytimes.in
Mizuho Maintains Assembly Biosciences (ASMB) Outperform Recommendation - Nasdaq
Assembly Biosciences (ASMB) Sees Raised Price Target From Mizuho - GuruFocus
Assembly Biosciences price target raised to $40 from $29 at Mizuho - TipRanks
Mizuho Raises Price Target on Assembly Biosciences to $40 From $29, Keeps Outperform Rating - marketscreener.com
How buyback programs support Assembly Biosciences Inc. (V7B) stockEarnings Recap Report & Entry Point Confirmation Alerts - newser.com
How Assembly Biosciences Inc. (V7B) stock benefits from digital adoption2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
What drives Assembly Biosciences Inc V7B stock priceEarnings Per Share Trends & Fast Profit Investment Ideas - earlytimes.in
What to do if you’re stuck in Assembly Biosciences Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Will Assembly Biosciences Inc. (V7B) stock benefit from Fed rate cuts2025 Price Targets & Weekly High Momentum Picks - newser.com
Is Assembly Biosciences Inc. (V7B) stock a buy during volatile marketsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Is Assembly Biosciences Inc. stock a buy before product launches2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
Assembly Biosciences Inc. stock momentum explainedWeekly Trade Recap & High Return Trade Guides - newser.com
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):